dcsimg Aranesp® (darbepoetin alfa) – Home
› Email› Print
One ESA. Multiple Options. Over 10 years in nephrology.

Isn’t it nice to know you have both?


Aranesp® provides the convenience of less frequent dosing through QW and Q2W dosing intervals compared to TIW dosing.1


Patients on dialysis can experience frequent changes in Hb levels. Hb can increase or Hb can decrease, for example, due to an unpredictable clinical event. Irrespective of the Hb change, Aranesp® allows for timely intervention.1-6

Abbreviations and References:
QW = once weekly; Q2W = once every 2 weeks; TIW = three times a week; Hb = hemoglobin.
References: 1. Aranesp® (darbepoetin alfa) prescribing information, Amgen. 2. Foley RN, Solid CA, Lamb K. Perihospitalization patterns of hemoglobin levels and erythropoiesis-stimulating agent doses in US hemodialysis patients, 1998-2009. Hemodial Int. 2014;18(1): 24-31. 3. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1(16):1205-1210. 4. Chan KE, Lazarus JM, Wingard RL, Hakim RM. Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge. Kidney Int. 2009;76(3);331-341. 5. Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant. 2009;24(3):919-925. 6. United States Renal Data System. 2013 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.

Biotechnology by Amgen®